An adenosine kinase mutant and its application in the catalytic preparation of adenosine triphosphate.
By performing site-directed mutagenesis on wild-type adenosine kinase of *Anopheles gambiae* at mutation sites A95S and/or Q202H, a co-expression strain was constructed, which solved the problem of low catalytic activity of wild-type adenosine kinase and achieved efficient conversion and low-cost production of adenosine to adenosine triphosphate.
Patent Information
- Application Number
- CN202611463662.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-20
- Publication Date
- 2026-11-17
AI Technical Summary
In existing technologies, the catalytic activity of wild-type adenosine kinases from natural sources is low, resulting in insufficient conversion efficiency of adenosine to AMP and ATP, and the mutation strategies of adenosine kinases from different sources are not universal.
By site-directed mutagenesis of wild-type adenosine kinase from Anopheles gambiae at mutation sites A95S and/or Q202H, a strain co-expressing adenosine kinase, adenosine kinase, and acetate kinase was constructed, and adenosine triphosphate was prepared using adenosine and acetyl phosphate as substrates.
It significantly improved the catalytic activity of adenosine kinase, making its enzyme activity 2 to 6 times that of the wild type, achieving efficient conversion of adenosine to adenosine triphosphate and reducing reaction cost and time.
Smart Images

Figure CN123107958A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of genetic engineering, specifically to an adenosine kinase mutant and its application in the catalytic preparation of adenosine triphosphate. Background Technology
[0002] Adenosine kinase (EC 2.7.1.20) is a key enzyme in the purine salvage pathway in organisms, catalyzing the reaction of adenosine with ATP to produce adenosine monophosphate (AMP). It is a core enzymatic element in the biocatalytic synthesis of AMP and downstream nucleotide compounds (such as adenosine diphosphate and adenosine triphosphate). Adenosine triphosphate (ATP) is a core molecule in bioenergy metabolism, with huge demand in the pharmaceutical, food, and biomanufacturing fields. Using inexpensive adenosine as a starting substrate, the preparation of ATP via a multi-enzyme cascade of "adenosine kinase + adenosine kinase + acetate kinase" is an important route to reduce ATP production costs. In this cascade system, adenosine kinase catalyzes the initial step of the entire reaction, and its catalytic activity directly determines the overall conversion rate of the cascade system, acting as the rate-limiting step restricting conversion efficiency. Therefore, obtaining adenosine kinase with high catalytic activity is crucial for achieving efficient conversion of adenosine to AMP and ATP.
[0003] However, existing technologies for naturally derived wild-type adenosine kinases generally suffer from low catalytic activity, high enzyme dosage, and insufficient conversion efficiency. To improve the catalytic performance of adenosine kinases, researchers have attempted to mutate wild-type adenosine kinases using protein engineering techniques. For example, Chinese patent CN202310202835 discloses a halophilic adenosine kinase mutant, which modifies wild-type adenosine kinase from *Candida parapolymorpha* to obtain a mutant with improved catalytic activity and salt tolerance, used for the synthesis of adenosine monophosphate from adenosine. However, adenosine kinases from different sources exhibit significant differences in amino acid sequence, spatial structure, and catalytic properties, and mutation sites and strategies obtained by screening for adenosine kinases from one source are not applicable to enzymes from other sources.
[0004] Therefore, in order to achieve efficient conversion of adenosine to adenosine triphosphate, improve the conversion efficiency of the adenosine kinase cascade system, and reduce the cost of enzyme preparations, it is of great industrial application value to explore other more active adenosine kinases. Summary of the Invention
[0005] The technical problem to be solved by the present invention is to provide a more active adenosine kinase mutant in order to overcome the shortcomings of the prior art.
[0006] Another technical problem to be solved by the present invention is to provide the application of the above-mentioned adenosine kinase mutant in the catalytic preparation of adenosine triphosphate.
[0007] To solve the above-mentioned technical problems, the technical solution adopted by the present invention is as follows:
[0008] In a first aspect, the present invention provides an adenosine kinase mutant, which is obtained by mutating the 95th A to S or the 202nd Q to H of wild-type adenosine kinase.
[0009] The wild-type adenosine kinase is derived from Anopheles gambiae, and its amino acid sequence is shown in SEQ ID NO.1. The corresponding nucleotide sequence encoding the wild-type adenosine kinase gene is shown in SEQ ID NO.2.
[0010] Specifically, the amino acid sequence of the adenosine kinase mutant, in which the A at position 95 of the wild-type adenosine kinase is mutated to S, is shown in SEQ ID NO.7.
[0011] Specifically, the adenosine kinase mutant with the wild-type adenosine kinase having a Q mutation at position 202 to H has the amino acid sequence shown in SEQ ID NO.9.
[0012] Furthermore, the present invention provides another adenosine kinase mutant, which is obtained by mutating the 95th A to S and the 202nd Q to H of the wild-type adenosine kinase.
[0013] The wild-type adenosine kinase is derived from Anopheles gambiae, and its amino acid sequence is shown in SEQ ID NO.1. The corresponding nucleotide sequence encoding the wild-type adenosine kinase gene is shown in SEQ ID NO.2.
[0014] Specifically, the amino acid sequence of the adenosine kinase mutant, in which the A at position 95 of the wild-type adenosine kinase is mutated to S and the Q at position 202 is mutated to H, is shown in SEQ ID NO.11.
[0015] In a second aspect, the present invention provides a nucleic acid molecule of the adenosine kinase mutant described in the first aspect.
[0016] Specifically, the nucleotide sequence of the adenosine kinase mutant, which mutates the A at position 95 of the wild-type adenosine kinase to S, is shown in SEQ ID NO.8.
[0017] Specifically, the nucleotide sequence of the adenosine kinase mutant, which mutates Q at position 202 of the wild-type adenosine kinase to H, is shown in SEQ ID NO.10.
[0018] Specifically, the nucleotide sequence of the adenosine kinase mutant, which mutates the A at position 95 of the wild-type adenosine kinase to S and the Q at position 202 to H, is shown in SEQ ID NO.12.
[0019] Thirdly, the present invention provides a recombinant expression vector containing the nucleic acid molecule described in the second aspect.
[0020] The recombinant expression vector also contains nucleic acid molecules of adenosine kinase and acetate kinase.
[0021] In some embodiments of the present invention, the adenosine kinase is derived from Citrobacter freundii, whose amino acid sequence is shown in SEQ ID NO.3, and whose nucleotide sequence is shown in SEQ ID NO.4.
[0022] In some embodiments of the present invention, the acetate kinase is derived from Citrobacter freundii, whose amino acid sequence is shown in SEQ ID NO.5, and the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.6.
[0023] The nucleotide sequences of the above-mentioned wild-type adenosine kinase, adenosine kinase and acetate kinase were synthesized in their entirety by General Biotechnology (Anhui) Co., Ltd.
[0024] Fourthly, the present invention provides a recombinant strain, which is obtained by introducing the coding gene of the nucleic acid molecule described in the second aspect into a host strain, or by introducing the coding gene of the nucleic acid molecule described in the second aspect into a host strain through the recombinant expression vector described in the third aspect.
[0025] In some embodiments of the present invention, the host strain is Escherichia coli BL21(DE3).
[0026] The recombinant strain, after induction and expression, showed that the activity of the adenosine kinase mutant was significantly improved by an enzyme activity assay system of 10 mL, with its enzyme activity being approximately 2 to 6 times that of wild-type adenosine kinase.
[0027] Specifically, the enzyme activity is defined as the amount of enzyme required to convert 1 μmol of adenosine per minute, calculated in units per gram of wet bacterial cells. Relative enzyme activity = mutant enzyme activity / wild-type adenosine kinase activity.
[0028] Fifthly, the present invention provides an adenosine kinase preparation containing the expression protein of the adenosine kinase mutant described in the first aspect.
[0029] In a sixth aspect, the present invention provides the application of the adenosine kinase mutant described in the first aspect in the catalytic preparation of adenosine triphosphate.
[0030] The catalysis involves using adenosine and acetyl phosphate as substrates to synthesize adenosine triphosphate via a three-enzyme cascade catalysis of adenosine kinase, adenosine kinase, and acetate kinase.
[0031] In some embodiments of the present invention, the catalysis is carried out using adenosine and acetyl phosphate as substrates, and adenosine kinase, adenosine phosphate, and acetate kinase co-expressing strains are used to catalyze the synthesis of adenosine triphosphate.
[0032] The catalytic reaction system comprises: 20-100 mM adenosine, 80-400 mM acetyl phosphate, 5-20 mM magnesium chloride, 0.5-2 mM adenosine triphosphate, 2-10 g / L adenosine kinase, adenosine kinase and acetate kinase co-expressing strain crude enzyme solution.
[0033] The catalysis is carried out under the following conditions: 35-40°C and pH 6.0-9.0 for 2-10 h. Preferably, the reaction is carried out at 37°C and pH 8.0 for 2-4 h.
[0034] In some embodiments of the present invention, the catalytic reaction system and conditions are as follows: 30 mM adenosine, 120 mM acetyl phosphate, 10 mM magnesium chloride, and 1 mM adenosine triphosphate are added to a 100 mL reaction system. After adjusting the pH to 8.0, crude enzyme solution of a co-expressing strain of adenosine kinase, adenosine kinase, and acetate kinase is added at 37°C to a final concentration of 3 g / L. After reacting for 2 h, 30 mM adenosine and 120 mM acetyl phosphate are added, and after adjusting the pH to 8.0, crude enzyme solution of a co-expressing strain of adenosine kinase, adenosine kinase, and acetate kinase is added again.
[0035] Beneficial effects:
[0036] This invention involves site-directed modification of wild-type adenosine kinase from *Anopheles gambiae*. The resulting mutant contains mutation sites A95S and / or Q202H, yielding adenosine kinase mutants with significantly enhanced activity, 2-6 times that of wild-type adenosine kinase. Furthermore, this invention constructs a co-expression strain of adenosine kinase, adenosine kinase, and acetate kinase. Using this strain with adenosine and acetyl phosphate as substrates, efficient production of adenosine triphosphate (ATP) can be achieved. This reaction utilizes adenosine, a less expensive substrate, is simpler to operate, has higher conversion efficiency, and shortens reaction time. Therefore, the adenosine kinase obtained through site-directed modification in this invention has extremely high catalytic application potential and broad application prospects in industrial settings. Attached Figure Description
[0037] The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments, and the advantages of the present invention in the above and / or other aspects will become clearer.
[0038] Figure 1 This is a recombinant expression vector containing the genes encoding adenosine kinase, adenosine kinase, and acetate kinase. Note: pET28a-AgAK-CfADK-CfACK in the figure is pET28a-AgAK. A95S-Q202H -CfADK-CfACK. Detailed Implementation
[0039] The present invention will be further described in detail below with reference to specific embodiments, and the advantages of the present invention in the above and / or other aspects will become clearer.
[0040] Unless otherwise specified, the experimental methods described in the following examples are conventional methods; unless otherwise specified, the reagents and materials are commercially available.
[0041] Example 1: Construction and expression of adenosine kinase, adenosine kinase and acetate kinase
[0042] The amino acid sequence of adenosine kinase from *Anopheles gambiae* is shown in SEQ ID NO.1, and the nucleotide sequence is shown in SEQ ID NO.2. The amino acid sequence of adenosine kinase from *Citrobacter freundii* is shown in SEQ ID NO.3, and the nucleotide sequence is shown in SEQ ID NO.4. The amino acid sequence of acetate kinase from *Citrobacter freundii* is shown in SEQ ID NO.5, and the nucleotide sequence is shown in SEQ ID NO.6. The genes for adenosine kinase, adenosine kinase, and acetate kinase were synthesized in their entirety by General Biotechnology (Anhui) Co., Ltd., and ligated into the pET28a vector to obtain recombinant plasmids pET28a-AgAK, pET28a-CfADK, and pET28a-CfACK. These recombinant plasmids were then transformed into *E. coli* BL21(DE3) competent cells to obtain the corresponding recombinant *E. coli* strains.
[0043] The recombinant *E. coli* strains were inoculated into 20 mL of LB medium containing 50 mg / L kanamycin and cultured at 37°C and 200 rpm for 12 hours. Then, they were transferred to 1 L of TB medium containing 50 mg / L kanamycin at a 1% v / v inoculation rate and cultured at 37°C and 200 rpm until OD500 was reached. 600When the concentration is 0.6~0.8, add IPTG to a final concentration of 0.2 mM, and continue induction culture at 28℃ and 200 rpm for 12~16 h. Centrifuge the culture at 8000 rpm for 10 min, collect the cells, and store them in a -80℃ freezer.
[0044] Example 2: Construction and expression of adenosine kinase mutant (single-point mutation)
[0045] The adenosine kinase mutant was constructed using whole-plasmid PCR, and the designed mutant primers are shown in Table 1. Using the plasmid pET28a-AgAK constructed in Example 1 as a template, PCR amplification was performed using the corresponding primers in Table 1. The PCR reaction system included: 5 μL 10×PCR Buffer, 5 μL 2 mM dNTPs, 3 μL 25 mM magnesium sulfate, 1.5 μL each of 10 pmol / μL primer F and primer R, 1 μL plasmid template, 1 μL KOD-Plus-Neo polymerase (purchased from Toyobo Co., Ltd.), and finally, sterile distilled water was used to bring the volume to 50 μL. The PCR reaction parameters were: 94℃ melting for 2 minutes, 98℃ denaturation for 10 seconds, 60℃ annealing for 30 seconds, 68℃ extension for 3 minutes and 30 seconds, for 30 cycles, with a final 5 minutes at 68℃, followed by storage at 4℃.
[0046] Table 1 Primer sequence list corresponding to the mutation sites of each single-point mutant
[0047]
[0048] The PCR product was digested with DpnI (purchased from TaKaRa) in the following reaction mixture: 8.5 μL PCR product, 1 μL 10×QuickCut Buffer, and 0.5 μL DpnI. The mixture was incubated at 37°C for 0.5 h, then transformed into *E. coli* BL21(DE3) competent cells and cultured on LB agar plates (containing 50 mg / L kanamycin) at 37°C for 12 h to obtain clones. Three clones from each culture were selected and cultured on LB agar (containing 50 mg / L kanamycin) at 37°C and 200 rpm for 12 hours before sequencing. After successful sequencing, the corresponding recombinant plasmid pET28a-AgAK was obtained. K55N pET28a-AgAK R79P pET28a-AgAK C88S pET28a-AgAK A95S pET28a-AgAK P118G pET28a-AgAK G188N pET28a-AgAK P201C pET28a-AgAK Q202HpET28a-AgAK G235P pET28a-AgAK R314K Then, the expression of each single-point mutant bacterial cell was induced, following the same process as the bacterial cell induction expression process in Example 1.
[0049] Example 3: Enzyme activity assay of adenosine kinase single-point mutant
[0050] The 10 mL reaction system consisted of 20 mM adenosine, 30 mM acetyl phosphate, 10 mM magnesium chloride, and 1 mM ATP. After adjusting the pH to 8.0, 2 g / L adenosine kinase cells, 0.5 g / L acetate kinase cells, and 0.2% Triton X-100 were added. The reaction was carried out at 37°C with shaking at 200 rpm. Samples were taken every 10 min and quenched by boiling in a water bath. The enzyme activity of adenosine kinase is defined as the amount of enzyme required to convert 1 μmol of adenosine substrate per minute, calculated in units per g of wet cells. Relative enzyme activity = mutant enzyme activity / wild-type adenosine kinase activity.
[0051] Table 2 Comparison of enzyme activities of wild-type adenosine kinase and single-point mutants
[0052]
[0053] The experimental results are shown in Table 2. It can be seen that only when the mutation sites are A95S and Q202H did the enzyme activity of the mutants significantly increase, and the corresponding relative enzyme activities were all greater than 200%. The relative enzyme activities of the mutants obtained by mutations at other sites were lower than those of wild-type adenosine kinase. Subsequently, combined mutations were performed using the A95S and Q202H sites. Specifically, the amino acid sequence of the adenosine kinase mutant A95S is shown in SEQ ID NO.7, and the corresponding nucleotide sequence is shown in SEQ ID NO.8; the amino acid sequence of the adenosine kinase mutant Q202H is shown in SEQ ID NO.9, and the corresponding nucleotide sequence is shown in SEQ ID NO.10.
[0054] Example 4: Construction, expression, and enzyme activity assay of adenosine kinase combinatorial mutants
[0055] Combinatorial mutations are obtained by using a plasmid of a single-point mutant as a template and then performing full-plasmid PCR construction. The specific process is as follows: using the single-point mutant A95S pET28a-AgAK... A95S Using the plasmid as a template, PCR amplification was performed with primers 202-F and 202-R. The PCR amplification process, enzyme digestion and transformation of the PCR product, and sequencing were all performed correctly to obtain pET28a-AgAK. A95S-Q202H The induction and expression process of the plasmid and the combined mutant A95S-Q202H bacterial cells was the same as in Example 2. Enzyme activity was detected in the combined mutant, following the same procedure as in Example 3.
[0056] Table 3 Comparison of enzyme activities of wild-type adenosine kinase and combined mutants
[0057]
[0058] The results are shown in Table 3. After combined mutation, the enzyme activity of the adenosine kinase mutant A95S-Q202H was further increased, with a relative enzyme activity more than 5 times that of the wild type. Specifically, the amino acid sequence of the adenosine kinase mutant A95S-Q202H is shown in SEQ ID NO.11, and the corresponding nucleotide sequence is shown in SEQ ID NO.12.
[0059] Example 5: Construction of a strain co-expressing adenosine kinase, adenosine kinase, and acetate kinase
[0060] To reduce bacterial load, the genes for three enzymes—adenosine kinase, adenosine kinase, and acetate kinase—were constructed into the same expression vector, pET28a. Based on the nucleotide sequence corresponding to the adenosine kinase mutant A95S-Q202H, upstream primer 1F and downstream primer 1R were designed and synthesized to express the adenosine kinase mutant A95S-Q202H in pET28a-AgAK. A95S-Q202H PCR amplification was performed using plasmids as templates. Based on the nucleotide sequence of adenosine kinase, upstream primer 2F and downstream primer 2R were designed and synthesized, and PCR amplification was performed using the pET28a-CfADK plasmid as a template. Based on the nucleotide sequence of acetate kinase, upstream primer 3F and downstream primer 3R were designed and synthesized, and PCR amplification was performed using the pET28a-CfACK plasmid as a template.
[0061] The PCR reaction system consisted of: 5 μL 10×PCR Buffer, 5 μL 2 mM dNTPs, 3 μL 25 mM magnesium sulfate, 1.5 μL each of 10 pmol / μL primer F and primer R, 1 μL template, 1 μL KOD-Plus-Neo polymerase, and finally, sterile distilled water to a final volume of 50 μL. The PCR reaction parameters were: 94℃ melting for 2 minutes, 98℃ denaturation for 10 seconds, 55℃ annealing for 30 seconds, 68℃ extension for 45 seconds, for 30 cycles, with a final 5 minutes at 68℃, followed by storage at 4℃. AgAK was recovered by 1% agarose gel electrophoresis using a DNA gel extraction kit (purchased from TaKaRa). A95S-Q202H DNA fragments of CfADK and CfACK.
[0062] Using upstream primer 1F and downstream primer 3R, with AgAK A95S-Q202HDNA fragments of CfADK and CfACK were used as templates for PCR amplification. The PCR reaction system consisted of: 5 μL 10×PCR Buffer, 5 μL 2 mM dNTPs, 3 μL 25 mM magnesium sulfate, 1.5 μL each of 10 pmol / μL primer F and primer R, 1 μL template, 1 μL KOD-Plus-Neo polymerase, and finally, sterile distilled water to a final volume of 50 μL. The PCR parameters were: 94℃ for 2 min of melting, 98℃ for 10 sec of denaturation, 55℃ for 30 sec of annealing, and 68℃ for 1 min 30 sec of extension, for 30 cycles, with a final 5 min extension at 68℃, followed by storage at 4℃. AgAK was obtained by gel extraction. A95S-Q202H DNA fragments of -CfADK-CfACK.
[0063] The sequence information of primers 1F, 1R, 2F, 2R, 3F, and 3R is shown in Table 4.
[0064] Table 4. Sequence information of primers 1F, 1R, 2F, 2R, 3F, and 3R.
[0065]
[0066] The amplified AgAK was cleaved using NdeI and XhoI restriction endonucleases (purchased from TaKaRa). A95S-Q202H The CfADK-CfACK gene fragment and pET-28a expression vector (purchased from Novagen) were digested with enzymes. The purified DNA fragment was ligated into the linearized pET28a expression vector after digestion. The ligation mixture consisted of 4 μL of purified DNA fragment, 6 μL of linearized pET28a expression vector, and 10 μL of Solution I. The mixture was incubated at 16°C for 2 h to obtain the recombinant expression vector pET28a-AgAK. A95S-Q202H -CfADK-CfACK ( Figure 1 The recombinant expression vector was then transformed into Escherichia coli BL21(DE3) competent cells to obtain recombinant Escherichia coli. After culturing at 37°C for 12 hours on LB plates (containing a final concentration of 50 mg / L Kan), single colonies were picked and cultured in LB medium at 37°C and 200 rpm (containing a final concentration of 50 mg / L Kan) for 12 hours before being sent for sequencing to determine the sequence.
[0067] The induction expression process for the correctly sequenced co-expression strain was the same as in Example 1. 2 g of bacterial cells were weighed into a 50 mL centrifuge tube, washed twice with 0.1 mol / L PBS (pH 7.5), centrifuged to collect the cells, and resuspended in 20 mL of 0.1 mol / L PBS (pH 7.5) to obtain a 100 g / L bacterial suspension. The cells were then disrupted using an ultrasonic disruptor in an ice-water bath. The instrument parameters were set to 200 W power, 3 s sonication followed by a 7 s pause, for approximately 40 min until the suspension became clear. After the disruption, the suspension was centrifuged at 4°C and 8000 rpm for 10 min, and the supernatant was collected as the crude enzyme solution of the co-expression strain.
[0068] Example 6: Application of strains co-expressing adenosine kinase, adenosine kinase, and acetate kinase in the catalytic preparation of adenosine triphosphate.
[0069] In a 100 mL reaction system, 30 mM adenosine, 10 mM magnesium chloride, 1 mM adenosine triphosphate, and 120 mM acetyl phosphate were added, and the pH was adjusted to 8.0. Then, 3 g / L of the crude enzyme solution of the co-expressing strain was added at 37°C. After 2 h of reaction, 30 mM adenosine and 120 mM acetyl phosphate were added again, and the pH was adjusted to 8.0. Finally, 3 g / L of the crude enzyme solution of the co-expressing strain was added again. After a final reaction of 4 h, the concentrations of ATP product (24.5 g / L), ADP byproduct (0.9 g / L), and substrate adenosine conversion rate (99%) were measured.
[0070] This invention provides an adenosine kinase mutant and its application in the catalytic preparation of adenosine triphosphate (ATP). Many methods and approaches exist for implementing this technical solution; the above description is merely a preferred embodiment. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principles of this invention, and these improvements and modifications should also be considered within the scope of protection of this invention. All components not explicitly stated in this embodiment can be implemented using existing technologies.
Claims
1. An adenosine kinase mutant, characterized in that, The adenosine kinase mutant is obtained by mutating the 95th A to S or the 202nd Q to H of the wild-type adenosine kinase. The amino acid sequence of the wild-type adenosine kinase is shown in SEQ ID NO.
1.
2. An adenosine kinase mutant, characterized in that, The adenosine kinase mutant was obtained by mutating the 95th position (A) of the wild-type adenosine kinase to S and the 202nd position (Q) to H. The amino acid sequence of the wild-type adenosine kinase is shown in SEQ ID NO.
1.
3. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes the adenosine kinase mutant as described in claim 1 or 2.
4. A recombinant expression vector, characterized in that, It contains the nucleic acid molecule as described in claim 3.
5. A recombinant bacterial strain, characterized in that, The recombinant strain is obtained by introducing the coding gene of the nucleic acid molecule described in claim 3 into a host strain through the recombinant expression vector described in claim 4.
6. An adenosine kinase preparation, characterized in that, The expressed protein contains the adenosine kinase mutant of claim 1 or claim 2.
7. The use of the adenosine kinase mutant according to claim 1 or 2 in the catalytic preparation of adenosine triphosphate.
8. The application according to claim 7, characterized in that, The catalysis uses adenosine and acetyl phosphate as substrates and utilizes a strain co-expressing adenosine kinase, adenosine kinase and acetate kinase to catalyze the synthesis of adenosine triphosphate.
9. The application according to claim 7, characterized in that, The catalysis reaction system consists of: 20-100 mM adenosine, 80-400 mM acetyl phosphate, 5-20 mM magnesium chloride, 0.5-2 mM adenosine triphosphate, 2-10 g / L adenosine kinase, adenosine kinase and acetate kinase co-expressing strain crude enzyme solution.
10. The application according to claim 8 or 9, characterized in that, The catalysis is carried out under the following conditions: 35~40℃, pH=6.0~9.0 for 2~10 h.
Citation Information
Patent Citations
A halophilic adenosine kinase mutant and its encoding gene and application
CN116376868B
